Prospective Grant of an Exclusive Patent License: Apparatus for Microarray Binding Sensors Having Biological Probe Materials Using Carbon Nanotube Transistors, 41970-41971 [2017-18668]
Download as PDF
mstockstill on DSK30JT082PROD with NOTICES
41970
Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–4866 for the ‘‘Pediatric PostMarketing Pharmacovigilance and Drug
Utilization Reviews’’ that have been
posted on FDA’s Web site between
March 11, 2017, and September 12,
2017, but not presented at the
September 12, 2017, PAC meeting.
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff office
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
VerDate Sep<11>2014
17:43 Sep 01, 2017
Jkt 241001
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Kenneth Quinto, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5145, Silver Spring,
MD 20993, 240–402–2221, email:
kenneth.quinto@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
responsible for protecting the public
health by assuring the safety, efficacy,
and security of human and veterinary
drugs, biological products, medical
devices, our Nation’s food supply,
cosmetics, and products that emit
radiation.
FDA is establishing a public docket,
Docket No. FDA–2017–N–4866, to
receive input on pediatric postmarketing pharmacovigilance and drug
utilization reviews posted between
March 11, 2017, and September 12,
2017, available on FDA’s Web site at
https://www.fda.gov/
AdvisoryCommittees/
CommitteesMeetingMaterials/
PediatricAdvisoryCommittee/
ucm510701.htm, but not presented at
the September 12, 2017, PAC meeting.
FDA welcomes comments by members
of the PAC, as mandated by the Best
Pharmaceuticals for Children Act (Pub.
L. 107–109) and the Pediatric Research
Equity Act (Pub. L. 108–155), interested
parties (such as academic researchers,
regulated industries, consortia, and
patient groups), and the general public.
The docket number is FDA–2017–N–
4866. The docket will open on October
9, 2017, and remain open until October
20, 2017. These pediatric postmarketing pharmacovigilance and drug
utilization reviews are for the following
products from the following centers at
FDA:
Center for Biologics Evaluation and
Research
1. GRASTEK (Timothy Grass Pollen
Allergen Extract) Tablet for
Sublingual Use
2. ORALAIR (Sweet Vernal, Orchard,
Perennial Rye, Timothy, and
Kentucky Blue Grass Mixed Pollens
Allergen Extract) Tablet for
Sublingual Use
Center for Drug Evaluation and
Research
1. ALOXI (palonosetron hydrochloride)
2. ARNUITY ELLIPTA (fluticasone
furoate)
3. ASMANEX HFA and ASMANEX
TWISTHALER (mometasone furoate
inhalation)
4. CYMBALTA (duloxetine)
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
5. EMSAM (selegiline transdermal
system)
6. LATISSE (bimatoprost ophthalmic
solution) 0.03%
7. NAMENDA (memantine
hydrochloride) and NAMENDA XR
(memantine hydrochloride)
extended-release
8. PRIFTIN (rifapentine)
9. REYATAZ (atazanavir)
10. TACLONEX (betamethasone
dipropionate/calcipotriene hydrate)
Topical Suspension 0.064%/
0.005% and TACLONEX
(betamethasone dipropionate/
calcipotriene hydrate) Topical
Ointment 0.064%/0.005%
11. ZETONNA (ciclesonide)
Dated: August 30, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–18690 Filed 9–1–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Apparatus for
Microarray Binding Sensors Having
Biological Probe Materials Using
Carbon Nanotube Transistors
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Nanobernetics, LLC
(‘‘Nanobernetics’’) located in Maryland.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before September 20, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Jaime M.
Greene, Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, Rm.
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702 Telephone: (240)-276–5530;
SUMMARY:
E:\FR\FM\05SEN1.SGM
05SEN1
Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices
Facsimile: (240)-276–5504 Email:
greenejaime@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
mstockstill on DSK30JT082PROD with NOTICES
EP Patent 1999277 (Application No.
07753436.0) filed 19 March 2007, titled
‘‘Apparatus for biosensor microarrays based
on carbon nanotube transistors having
biological probe materials, method for its
production and method of electronically
detecting a biological target material’’,
validated in FR, DE, IE, and GB, HHS
Reference No.: E–056–2007/0–EP–04;
Australia Patent 2007227415 (Application
No. 2007227415) filed 10/16/08, titled
‘‘Apparatus for microarray binding sensors
having biological probe materials using
carbon nanotube transistors’’, HHS Reference
No.: E–056–2007/0–AU–05;
Canada Patent 2646465 (Application No.
2646465) filed 03/19/07, titled ‘‘Apparatus
for microarray binding sensors having
biological probe materials using carbon
nanotube transistors’’, HHS Reference No.: E–
056–2007/0–CA–06;
Japan Patent 5048752 (Application No.
2009–501490) filed 03/19/07, titled
‘‘Apparatus for microarray binding sensors
having biological probe materials using
carbon nanotube transistors’’, HHS Reference
No.: E–056–2007/0–JP–07;
EP Patent 2570490 (Application No.
12160369.0) filed 03/19/07, titled ‘‘Apparatus
for microarray binding sensors having
biological probe materials using carbon
nanotube transistors’’, validated in FR, DE,
and GB. HHS Reference No.: E–056–2007/0–
EP–08;
U.S. Patent 8,017,938 (Application No. 11/
723,369), filed 19 March 2007, titled
‘‘Apparatus for Microarray Binding Sensors
Having Biological Probe Materials Using
Carbon Nanotube Transistors’’, HHS Ref. No.:
E–056–2007/0–US–03; and
PCT Application No. PCT/US2007/06809,
filed 19 March 2007, now abandoned, titled
‘‘Apparatus for Microarray Binding Sensors
Having Biological Probe Materials Using
Carbon Nanotube Transistors’’, HHS Ref. No.:
E–056–2007/0–PCT–02.
U.S. Provisional Patent Application No.
60/743,524, filed 17 March 2006, now
abandoned, titled ‘‘Apparatus for Microarray
DNA Binding Sensors Using Carbon
Nanotube Transistors’’, HHS Ref. No.: E–056–
2007/0–US–01.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘The
development of an FDA-approved or
cleared in vitro diagnostic for the
detection of hematological
malignancies, wherein nucleic acids
encoding one or more of the following
genes are detected: (1) BCR–ABL, (2)
FLT3, (3) Btk, (4) Alk, (5) Bcl–2, (6) Akt,
and (7) PI3K.’’
This technology discloses a
microarray apparatus that uses carbon
VerDate Sep<11>2014
17:43 Sep 01, 2017
Jkt 241001
nanotubes transistors and electronic
circuitry to quantitatively measure
changes in gene expression levels.
Typically, microarrays are microscope
glass slides spotted with thousands of
different genes. The array does not have
built-in reader, and the detection is
performed using a fluorescence scanner
after hybridization with fluorescenttagged target DNA. For simple nucleic
acid detection, current methods rely
upon various combinations of
enzymatic amplification of nucleic acids
and fluorescent labeling of targets,
which entail enzymatic manipulation of
the nucleic acid being tested and
chemical labeling, respectively. These
methods are both time consuming and
afford limited sensitivity. In cases where
microarray technology is used as a tool
for monitoring gene expression patterns
and profiling of micro RNA (miRNA) in
normal and cancerous tissue,
quantification of changes has typically
been optically-based. While this
technique is highly sensitive, use of
optical methods impedes progress in
both system miniaturization and in
direct interfacing with data collection
electronics.
To overcome the limitation of current
microarray technologies, the inventors
have developed a highly sensitive
microarray apparatus that uses carbon
nanotube transistors for the electronic
detection of biological probe-target
binding. The present invention provides
an apparatus for biological target
material detection which uses an array
of carbon nanotube transistors, with
each being operated as a field effect
transistor. A single carbon nanotube
transistor is associated with a distinct
biological probe material. The current
versus voltage characteristics or
transconductance between the source
and drain electrodes is measured before
and after a binding event between the
biological probe and target materials. By
using a mathematical relationship, the
exact amount of target binding can be
extracted. Importantly, the present
apparatus offers a significant advantage
in simplicity of protocol as the method
used therewith does not require
chemical or enzymatic manipulation of
the target being detected.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
41971
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 25, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–18668 Filed 9–1–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; NCI Cancer Genetics
Services Directory Web-Based
Application and Update Mailer
(National Cancer Institute)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI) will
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Margaret Beckwith, Office of
Cancer Content, Office of
Communications and Public Liaison
(OCPL), 9609 Medical Center Drive,
Rockville, MD 20892 or call non-tollfree number 240–276–6600 or email
your request, including your address to:
nciocpl@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\05SEN1.SGM
05SEN1
Agencies
[Federal Register Volume 82, Number 170 (Tuesday, September 5, 2017)]
[Notices]
[Pages 41970-41971]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18668]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Apparatus for
Microarray Binding Sensors Having Biological Probe Materials Using
Carbon Nanotube Transistors
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Commercialization Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
notice to Nanobernetics, LLC (``Nanobernetics'') located in Maryland.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before September 20, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Commercialization
Patent License should be directed to: Jaime M. Greene, Senior Licensing
and Patenting Manager, NCI Technology Transfer Center, 9609 Medical
Center Drive, Rm. 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business
mail), Rockville, MD 20850-9702 Telephone: (240)-276-5530;
[[Page 41971]]
Facsimile: (240)-276-5504 Email: greenejaime@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
EP Patent 1999277 (Application No. 07753436.0) filed 19 March
2007, titled ``Apparatus for biosensor microarrays based on carbon
nanotube transistors having biological probe materials, method for
its production and method of electronically detecting a biological
target material'', validated in FR, DE, IE, and GB, HHS Reference
No.: E-056-2007/0-EP-04;
Australia Patent 2007227415 (Application No. 2007227415) filed
10/16/08, titled ``Apparatus for microarray binding sensors having
biological probe materials using carbon nanotube transistors'', HHS
Reference No.: E-056-2007/0-AU-05;
Canada Patent 2646465 (Application No. 2646465) filed 03/19/07,
titled ``Apparatus for microarray binding sensors having biological
probe materials using carbon nanotube transistors'', HHS Reference
No.: E-056-2007/0-CA-06;
Japan Patent 5048752 (Application No. 2009-501490) filed 03/19/
07, titled ``Apparatus for microarray binding sensors having
biological probe materials using carbon nanotube transistors'', HHS
Reference No.: E-056-2007/0-JP-07;
EP Patent 2570490 (Application No. 12160369.0) filed 03/19/07,
titled ``Apparatus for microarray binding sensors having biological
probe materials using carbon nanotube transistors'', validated in
FR, DE, and GB. HHS Reference No.: E-056-2007/0-EP-08;
U.S. Patent 8,017,938 (Application No. 11/723,369), filed 19
March 2007, titled ``Apparatus for Microarray Binding Sensors Having
Biological Probe Materials Using Carbon Nanotube Transistors'', HHS
Ref. No.: E-056-2007/0-US-03; and
PCT Application No. PCT/US2007/06809, filed 19 March 2007, now
abandoned, titled ``Apparatus for Microarray Binding Sensors Having
Biological Probe Materials Using Carbon Nanotube Transistors'', HHS
Ref. No.: E-056-2007/0-PCT-02.
U.S. Provisional Patent Application No. 60/743,524, filed 17
March 2006, now abandoned, titled ``Apparatus for Microarray DNA
Binding Sensors Using Carbon Nanotube Transistors'', HHS Ref. No.:
E-056-2007/0-US-01.
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: ``The development of an FDA-
approved or cleared in vitro diagnostic for the detection of
hematological malignancies, wherein nucleic acids encoding one or more
of the following genes are detected: (1) BCR-ABL, (2) FLT3, (3) Btk,
(4) Alk, (5) Bcl-2, (6) Akt, and (7) PI3K.''
This technology discloses a microarray apparatus that uses carbon
nanotubes transistors and electronic circuitry to quantitatively
measure changes in gene expression levels. Typically, microarrays are
microscope glass slides spotted with thousands of different genes. The
array does not have built-in reader, and the detection is performed
using a fluorescence scanner after hybridization with fluorescent-
tagged target DNA. For simple nucleic acid detection, current methods
rely upon various combinations of enzymatic amplification of nucleic
acids and fluorescent labeling of targets, which entail enzymatic
manipulation of the nucleic acid being tested and chemical labeling,
respectively. These methods are both time consuming and afford limited
sensitivity. In cases where microarray technology is used as a tool for
monitoring gene expression patterns and profiling of micro RNA (miRNA)
in normal and cancerous tissue, quantification of changes has typically
been optically-based. While this technique is highly sensitive, use of
optical methods impedes progress in both system miniaturization and in
direct interfacing with data collection electronics.
To overcome the limitation of current microarray technologies, the
inventors have developed a highly sensitive microarray apparatus that
uses carbon nanotube transistors for the electronic detection of
biological probe-target binding. The present invention provides an
apparatus for biological target material detection which uses an array
of carbon nanotube transistors, with each being operated as a field
effect transistor. A single carbon nanotube transistor is associated
with a distinct biological probe material. The current versus voltage
characteristics or transconductance between the source and drain
electrodes is measured before and after a binding event between the
biological probe and target materials. By using a mathematical
relationship, the exact amount of target binding can be extracted.
Importantly, the present apparatus offers a significant advantage in
simplicity of protocol as the method used therewith does not require
chemical or enzymatic manipulation of the target being detected.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Commercialization Patent
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: August 25, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-18668 Filed 9-1-17; 8:45 am]
BILLING CODE 4140-01-P